Market Overview

Global Infection Control Market size was valued at around USD 228.12 billion in 2023 and is expected to reach a value of USD 405.50 billion by 2032, at a CAGR of 6.6% over the forecast period (2024–2032).

The market is mainly propelled by the increasing quantity of surgical and clinical procedures significantly reliant on infection prevention strategies. This strong need can be described as resulting from the favourable clinical outcomes related to successful infection control. The spread of the COVID-19 disease also enhanced the growth of the market through accelerated demand for sterilization and disinfection among hospitals, clinics, pharmaceutical firms, and medical equipment manufacturers. For example, CNBC indicated a 60% increase in U.S. manufacturing of sanitizer products during the pandemic and identified the future growth potential for infection control solutions.

The market is also growing as a result of increased outsourcing of sterilization services and the evolution of sophisticated sterilization technologies. Government policies to encourage strict infection prevention practices are another major driver. These include international bodies like the World Health Organization (WHO), which has published detailed guidelines for the management of pandemic- and epidemic-prone acute respiratory diseases in healthcare facilities. These guidelines encompass a variety of interventions, from simple hand hygiene and the donning of personal protective equipment to more sophisticated disinfection and sterilization procedures.

WHO statistics reveal that acute respiratory diseases (ARDs) are a major cause of mortality globally, with an estimated 4 million deaths per year. Such statistics highlight the imperative for effective infection prevention and control. Hospital-acquired infections (HAIs), such as bloodstream infections, surgical site infections, pneumonia, and MRSA, are also major issues since they complicate patient recovery and lead to increased mortality rates globally.

From an estimated WHO practical guide, operation infections increase stays in hospitals for approximately eight days on average. The increased prolonged stays contribute to the cost of hospitalization overall, thus strengthening the need to implement infection preventive measures. Protracted stays also impose significant monetary burdens on care providers and the payers through unnecessary use of resources, ranging from extra medicines, investigations, and lab testing equipment. All this unequal expenditure further accentuates the need to have proper measures for infection prevention.

Market Drivers

Long-term care facilities (LTCFs)

• European nations with long-term care facility (LTCF) surveillance systems have reported that deaths due to COVID-19 represent 5–6% of LTCF residents at present, and as many as 66% of all deaths among these residents. LTCF COVID-19 outbreaks can be especially catastrophic because of the older age and comorbid conditions of residents, which greatly elevate the risk of severe disease. Moreover, the quick transmission of the virus in LTCFs can overburden their ability to respond appropriately, thus emphasizing the importance of preparedness to contain outbreaks.
• Non-pharmaceutical interventions, such as personal contact restrictions or restricted access to healthcare services, can also further enhance the social vulnerabilities of LTCF residents. These interventions may inadvertently affect their well-being and access to required care.

Growing number of surgeries

• There has been an incredible growth in the number of surgical procedures carried out across the globe. The Lancet Commission on Global Surgery (LCOGS), according to a 2021 NCBI report, recommends that each country aim at 5,000 procedures per 100,000 inhabitants, along with a density of 20 specialists per 100,000 inhabitants in order to enhance the availability of surgical services. All this is caused by various factors that include the increasing prevalence of obesity, lifestyle diseases, population aging, as well as more spinal and sports-related injuries. As such, surgical equipment and medical devices are in more demand. The trend, in this case, highlights the necessity of infection control products and services, which have been proven to be useful in medical facilities. With more frequent surgeries, infection control is essential to prevent healthcare-associated infections (HAIs) and surgical site infections (SSIs). For example, a 2023 NCBI report notices a significant surge in cosmetic procedures in 2021 compared to other years. The surge in surgeries is a reflection of the increased need for infection control procedures, which will likely drive future adoption of infection control technologies, hence driving market growth.

Market Opportunities

Growing utilization of E-beam sterilization

• Electron-beam irradiation or beta irradiation is a widely practiced method for the sterilization of pharmaceutical packaging and medical equipment. This technique involves passing a beam of continuous electrons through the items to be sterilized. Though capable of sterilizing low- to medium-density products, it may fail for high-density products. One of the principal advantages of electron-beam irradiation is that it is able to achieve terminal sterilization quickly by simple on/off technology, using carcinogenic gas or radioactive sources, and without residual effects, which allows for the immediate release of the product.
• The increasing usage of electron-beam sterilization in different industries is likely to propel substantial market growth. This process has several advantages over other processes. For instance, the irradiation times are short, minimizing the radiation compatibility problems normally associated with other forms of sterilization. Total process time, incorporating transport, ranges from five to seven minutes and is considerably faster than gamma sterilization and ethylene oxide (EtO), taking hours or days. According to the International Atomic Energy Agency, more than 160 gamma irradiation sites around the world sterilize nearly 12 million cubic meters of medical devices a year, and that is greater than 40% of single-use medical devices used globally. Moreover, the hassle-free incorporation of electron-beam technology into manufacturing lines saves on costs, eliminates handling, and reduces related risks.

Market Restraining Factors

Impact of Health Care-Associated Infections in Low- and Middle-Income Counties

• In low-resource settings, surgical site infections (SSIs) occur in more than one-third of surgical patients, a rate that is greater than ninefold that in more affluent countries. In most instances, patients have to cover the extra charges of drugs and associated costs. Newborns and women in low- and middle-income countries (LMICs) are at a much greater risk of healthcare-associated infections (HAIs), with infection rates three to 20 times greater than those in high-income countries. In LMIC ICU patients, HAI rates are two to three times greater, and device-associated infections, including catheter or central line infections, are up to 13 times more frequent than in the United States.
• The impact of HAIs is particularly worrisome in LMICs because their treatment leads to longer hospital stays and involves additional resources that could be used to treat other patients. Studies have shown that the length of stay due to HAIs can be lengthened by as much as 5 to 29.5 days. HAIs also cause more use of antibiotics, more patient care items, and additional diagnostic tests, all of which drive up healthcare costs. In addition to the expense, HAIs cause psychological distress for patients and their families, which is translated into long-term effects on their health and reduces the quality of life. Also, HAIs are able to negatively impact the image of health care facilities since communities' realization of infections gained within health facilities spreads and engulfs others with fear while it influences how well patients can accept health care.

High cost associated with endoscopy reprocessing coupled with the limited reimbursements in developing nations

• High-end costs of reprocessing endoscopy, coupled with low reimbursements from developing nations, are a great hindrance in the expansion of the infection control market. High costs of acquiring equipment, upkeep, and maintenance, as well as cleaning solution, are specific challenges for reprocessing endoscopes that have been difficult to meet for medical practitioners in facilities with limited resources. In most developing countries, insufficient government reimbursements further tighten healthcare facilities' resources, preventing them from investing in infection control programs. For instance, the NCBI states that the price for a colonoscopy, ranging from acquisition, maintenance, and refurbishment, varies from US$188.64 at high-volume centres with 3,000 procedures done per year to US$501.16 at low-volume centres with 1,000 procedures done per year. Also, training of personnel and regular maintenance are necessary for efficient endoscopy management, adding to costs. Consequently, endoscopy procedures are still costly, particularly in Asian nations with minimal government reimbursements, leading to seeking cheaper alternatives. All these combines to make it challenging to practice effective infection control in endoscopy procedures in developing countries.

Segmentation Analysis

The market scope is segmented because of by Type, by End-use.

• By Type

Based on the Type of the market is segmented into Equipment, Services, Consumables.

The market for infection control worldwide is segmented into equipment, services, and consumables. In 2022, the consumable segment was the market leader, accounting for the highest revenue share. The reason behind this leadership is mainly because consumable products have a frequent usage and a low life cycle. Consumables are an essential part of disinfection, sterilization, and infection control processes, which increases their high market share. Within consumables, personal protective equipment (PPE) accounted for a significant portion of the market as of 2023.

The equipment segment is also sub-divided into sterilization equipment and disinfectors. Disinfectors are sub-divided into endoscope preprocessors, flushes, and washers. Sterilization equipment is sub-divided into liquid sterilization equipment, filtration sterilization, radiation sterilization, low-temperature sterilization, and heat sterilization equipment. Consumables are also sub-divided into other related products, PPE, sterilization consumables, disinfectants, and infectious waste disposal.

Healthcare institutions are more and more encouraging the application of personal protective equipment, and this is projected to keep pushing its market share. For example, W&H company launched the LEXA PLUS CLASS B sterilizer, a state-of-the-art device aimed at enhancing reprocessing and infection control in dental practices.

The services segment is expected to expand at the highest compound annual growth rate (CAGR) over the forecast period. This high growth is fuelled by market players' efforts to lower overall healthcare spending while optimizing benefits like cost savings, enhanced service efficiency, and increased productivity. Firms also prioritize guidelines and recommendations to prevent the transmission of respiratory pathogens among healthcare workers and staff. Services are divided into infectious waste disposal and contract sterilization. Contract sterilization sub-segment comprises e-beam sterilization, gamma sterilization, ethylene oxide sterilization, and other technologies.

• By End-use

Based on the End-use of the market is segmented into Hospitals, Medical Device Companies, Clinical Laboratories, Pharmaceutical Laboratories, Others.

The infection control market worldwide on the basis of end use is segmented into clinical laboratories, medical device manufacturers, pharmaceutical firms, hospitals, and others. The hospital segment led the market in 2023 with a share of around 42% of the total revenue and is expected to exhibit the highest compound annual growth rate (CAGR) of 7.5% between 2024-2032. The highest market share of this segment is largely due to the increased risk of infection within hospitals, particularly due to the transmission of blood-borne or respiratory pathogens. Hospital-acquired infections (HAIs) are one of the biggest issues faced by the healthcare industry, and stringent infection control practices are a must.

40% to 60% of infections in hospitals have been reported by studies to be associated with the surgical site, raising the demand for effective infection control practices. Operating room risk of high infection is one of the significant concerns, especially due to infectious organisms such as drug-resistant pathogens and blood-borne pathogens. The use of medical devices such as urinary catheters raises the risk of urinary tract infections (UTIs) and catheter-associated UTIs (CA-UTIs). According to the National Centre for Biotechnology Information (NCBI), UTIs account for 25% of all bacterial infections, and the National Nosocomial Infection Surveillance (NNIS) system has reported CA-bacteriuria and catheterization to be accountable for 40% of HAIs in the United States annually.

These issues are part of the factors driving the enhanced need for infection control products and services in hospitals, thereby increasing the market's growth opportunities over the next couple of years.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominated the infection control industry in 2023 with a share of more than 31% of the revenue. This dominance is owed largely to the high number of strategic partnerships among the industry's major players and the increased development of their infection control facilities and products across the region. One of the foremost cases is that of Advanced Sterilization Products (ASP), which introduced STERRAD 100NX System with ALLClear in the U.S. during January 2017, aimed at expanding its presence in Europe, Africa, and the Middle East. In 2020, ASP even obtained 510(k) clearance from the Food and Drug Administration (FDA) of the U.S. for the STERRAD VELOCITY Biological Indicator, providing healthcare professionals with the shortest sterilization procedure for instruments. The immense significance attributed by the companies to market expansion and innovation has significantly helped in the domination of North America in the infection control industry.

On the other hand, the Asia Pacific region is anticipated to grow the most in the infection control market with a projected compound annual growth rate (CAGR) of 8.3% between 2023 and 2030. This is driven by numerous factors such as the growing outsourcing of infection control services, higher healthcare spending, and enhanced healthcare infrastructure and standards within the region. Governments are also focusing more on improving infection control practices, which also contributes to market growth. The increasing trend of offshoring infection control services from the developed world to Asia Pacific nations is another prime driving force. Other organizations such as the Asia Pacific Society of Infection Control (APSIC) are also actively engaged in collaborative partnerships and studies with a view to improving infection control practices in the region, which will have a tendency to propel further development in the market.

List of Companies Profiled

• 3M
• Belimed AG
• O&M Halyard or its affiliates.
• Getinge Group
• ASP
• MATACHANA
• Sterigenics U.S., LLC – A Sotera Health company
• MMM Group
• Cantel Medical Corp.
• STERIS plc.
• Midmark Corporation.
• Medivators Inc
• W&H

Key Industry Developments

In October 2023, US market leading provider of innovative instrument care and infection control products is Getinge AB (Sweden) Healthmark Industries Co. Inc. The presence of Getinge in US sterile reprocessing is fortified by this strategic move. Ecolab INC. (US) launched Ecolab Scientific Clean, a new consumer retail brand of cleaning products for home, business, and industrial usage, in February 2023.

In October 2021, Thermo Fisher Scientific and 3M (US) collaborated in order to provide an opportunity to utilize the 3M Harvest RC Chromatographic Clarifier for biopharmaceutical customers.

Report Coverage

The report will cover the qualitative and quantitative data on the global Infection Control Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Infection Control Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Infection Control market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Infection Control. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Infection Control companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Infection Control Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Infection Control Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Infection Control Market valued?
• Which region has the largest share in 2024 for the global Infection Control Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Infection Control Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Infection Control Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: